Evidence map›Paper›PMID 30712923›Full record

Trial reportKidney international2019

A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.

Fabian Hammer, Uwe Malzahn, Julian Donhauser, Christoph Betz, Markus P Schneider, Clemens Grupp, Nils Pollak, Stefan Störk, Christoph Wanner, Vera Krane and 1 more

Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Kidney international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 10 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 10 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Guideline
  11. Trial
  12. The effect of spironolactone on diastolic function in haemodialysis patients.The international journal of cardiovascular imaging · 2021
    Trial
  13. Mineralocorticoid Receptor Antagonists in Dialysis.American journal of nephrology · 2026
    Review
  14. The Synergistic Treatment of Heart and Kidney Disease.Deutsches Arzteblatt international · 2026
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Mineralocorticoid receptor antagonism for non-diabetic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Fabian HammerDepartment of Medicine I, Division of Cardiology, University Hospital Würzburg, Würzburg, Germany; Comprehensive Heart Failure Center, University and University Hospital Würzburg, Würzburg, Germany; Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany. Electronic address: fabian.hammer@uni-greifswald.de.
Uwe MalzahnClinical Trial Center, University Hospital Würzburg, Würzburg, Germany.
Julian DonhauserDepartment of Diagnostic and Interventional Radiology, University of Würzburg, Würzburg, Germany.
Christoph BetzMedical Clinic III, Department of Nephrology, University Hospital Frankfurt, Frankfurt, Germany.
Markus P SchneiderDepartment of Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany.
Clemens GruppDepartment of Nephrology and Hypertension, Sozialstiftung Bamberg, Bamberg, Germany.
Nils PollakDepartment of Pharmacy, University Hospital Würzburg, Würzburg, Germany.
Stefan StörkDepartment of Medicine I, Division of Cardiology, University Hospital Würzburg, Würzburg, Germany; Comprehensive Heart Failure Center, University and University Hospital Würzburg, Würzburg, Germany.
Christoph WannerComprehensive Heart Failure Center, University and University Hospital Würzburg, Würzburg, Germany; Department of Medicine I, Division of Nephrology, University Hospital Würzburg, Würzburg, Germany.
Vera KraneComprehensive Heart Failure Center, University and University Hospital Würzburg, Würzburg, Germany; Department of Medicine I, Division of Nephrology, University Hospital Würzburg, Würzburg, Germany.
MiREnDa Study Group
Universitätsklinikum Würzburg · DEUniversitätsklinikum Erlangen · DEUniversity of Würzburg · DESozialstiftung Bamberg · DEGoethe University Frankfurt · DEUniversitätsmedizin Greifswald · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mineralocorticoid receptor antagonists have beneficial effects on left ventricular remodeling, cardiac fibrosis, and arrhythmia in heart failure, but efficacy and safety in dialysis patients is less clear. We evaluated the effect of spironolactone on left ventricular mass (LVM), an independent predictor of all-cause and cardiovascular mortality, in hemodialysis patients. In this placebo-controlled, parallel-group trial, 97 hemodialysis patients (23% female; mean age 60.3 years) were randomized to spironolactone 50 mg once daily (n=50) or placebo (n=47). The primary efficacy endpoint was change in LVM index (LVMi) from baseline to 40 weeks as determined by cardiac magnetic resonance imaging. Safety endpoints were development of hyperkalemia and change in residual renal function. There was no significant change in LVMi in participants randomized to spironolactone compared to placebo (-2.86±11.87 vs. 0.41±10.84 g/m

Indexed as

AgedDouble-Blind MethodFemaleHeart FailureHeart VentriclesHumansHyperkalemiaKidney Failure, ChronicMagnetic Resonance ImagingMaleMiddle AgedMineralocorticoid Receptor AntagonistsPlacebosRenal DialysisSpironolactoneStroke VolumeMineralocorticoid Receptor AntagonistsPlacebosSpironolactoneblood pressurehemodialysisleft ventricular mass indexpotassiumspironolactone

Identifiers

PMID30712923
OpenAlexW2912440708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.